BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Yorvipath (palopegteriparatide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Yorvipath (palopegteriparatide)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07081997-10863@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07081997)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Phase 3 Randomized Clinical Trial to Investigate the Safety and
  Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult
  Participants With Hypoparathyroidism\nEstimated primary completion: June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/palopegteripara
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07081997
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706764-10863@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07706764)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Study to Test the Effects and Safety of Palopegteriparatide in 
 Adolescents With Long-term Hypoparathyroidism\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palop
 egteriparatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07706764
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
